Abstract
We treated 21 patients with stage D prostatic adenocarcinoma who had had unsuccessful hormonal therapy with a combination of 600 mg. per M.2 per day estramustine phosphate and 15 mg. per M.2 per day prednismustine in daily oral doses. Estramustine is a combination of estradiol and nitrogen mustard, and alone has shown objective responses in advanced prostatic cancer. Prednimustine is an ester of chlorambucil and prednisone. The preliminary results (after 2 to 9 months of therapy) show 5 patients (24 per cent) with objective responses and 9 (44 per cent) with subjective improvement. Only 5 patients (24 per cent) did not benefit from the drug and 7 patients (33 per cent) are stable. These preliminary results indicate the possible advantage of adding an alkylating agent (prednimustine) to estramustine in advanced prostatic carcinoma.
Original language | English |
---|---|
Pages (from-to) | 332-336 |
Number of pages | 5 |
Journal | Journal of Urology |
Volume | 117 |
Issue number | 3 |
DOIs | |
State | Published - 1977 |
Externally published | Yes |